Richard Bruce Pearson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/440048/publications.pdf

Version: 2024-02-01

134 papers	14,737 citations	15504 65 h-index	19190 118 g-index
140 all docs	140 docs citations	140 times ranked	17680 citing authors

#	Article	IF	Citations
1	Protein kinase recognition sequence motifs. Trends in Biochemical Sciences, 1990, 15, 342-346.	7.5	1,036
2	[3] Protein kinase phosphorylation site sequences and consensus specificity motifs: Tabulations. Methods in Enzymology, 1991, 200, 62-81.	1.0	983
3	Mutation of the PIK3CA Gene in Ovarian and Breast Cancer. Cancer Research, 2004, 64, 7678-7681.	0.9	864
4	Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO Journal, 1997, 16, 3693-3704.	7.8	833
5	Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell, 2012, 22, 51-65.	16.8	468
6	The Akt kinase signals directly to endothelial nitric oxide synthase. Current Biology, 1999, 9, 845-S1.	3.9	445
7	A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. Journal of Biological Chemistry, 1986, 261, 989-92.	3.4	444
8	mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBFâ€. Molecular and Cellular Biology, 2003, 23, 8862-8877.	2.3	390
9	Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discovery, 2014, 4, 423-433.	9.4	242
10	Regulatory and structural motifs of chicken gizzard myosin light chain kinase.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2284-2288.	7.1	223
11	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene, 2012, 31, 1949-1962.	5.9	221
12	STIM1: a novel phosphoprotein located at the cell surface. BBA - Proteins and Proteomics, 2000, 1481, 147-155.	2.1	209
13	Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors, 2007, 25, 209-226.	1.7	204
14	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews in Oncogenesis, 2012, 17, 69-95.	0.4	204
15	Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell, 2011, 20, 635-648.	16.8	203
16	Targeting the nucleolus for cancer intervention. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 802-816.	3.8	198
17	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	12.8	192
18	Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nature Reviews Cancer, 2013, 13, 299-314.	28.4	187

#	Article	IF	Citations
19	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. Journal of Clinical Investigation, 2012, 122, 553-557.	8.2	174
20	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PLoS ONE, 2011, 6, e18064.	2.5	172
21	UBF levels determine the number of active ribosomal RNA genes in mammals. Journal of Cell Biology, 2008, 183, 1259-1274.	5.2	171
22	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO Journal, 2004, 23, 3325-3335.	7.8	166
23	Loss of <scp>CDKN</scp>2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the <scp>CDK</scp>4/6 inhibitor <scp>PD</scp>0332991 in melanoma cell lines. Pigment Cell and Melanoma Research, 2014, 27, 590-600.	3.3	165
24	The calmodulin binding domain of chicken smooth muscle myosin light chain kinase contains a pseudosubstrate sequence. Journal of Biological Chemistry, 1987, 262, 2542-8.	3.4	164
25	Autoregulation of enzymes by pseudosubstrate prototopes: myosin light chain kinase. Science, 1988, 241, 970-973.	12.6	162
26	Rapamycin, Wortmannin, and the Methylxanthine SQ20006 Inactivate p70s6k by Inducing Dephosphorylation of the Same Subset of Sites. Journal of Biological Chemistry, 1995, 270, 21396-21403.	3.4	161
27	Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6406-6411.	7.1	159
28	Substrate specificity of a multifunctional calmodulin-dependent protein kinase. Journal of Biological Chemistry, 1985, 260, 14471-6.	3.4	151
29	Intrasteric regulation of protein kinases and phosphatases. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1094, 67-76.	4.1	146
30	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery, 2019, 9, 1036-1049.	9.4	129
31	Second AKT: The rise of SGK in cancer signalling. Growth Factors, 2010, 28, 394-408.	1.7	127
32	Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 323.	17.1	127
33	Structural basis of the intrasteric regulation of myosin light chain kinases. Science, 1992, 258, 130-135.	12.6	126
34	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. Science Signaling, 2011, 4, ra56.	3.6	126
35	Phosphorylation Sites in the Autoinhibitory Domain Participate in p70s6k Activation Loop Phosphorylation. Journal of Biological Chemistry, 1998, 273, 14845-14852.	3.4	122
36	[10] Design and use of peptide substrates for protein kinases. Methods in Enzymology, 1991, 200, 121-134.	1.0	116

#	Article	IF	Citations
37	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling, 2015, 8, ra82.	3.6	114
38	Differential Regulation by Calcium Reveals Distinct Signaling Requirements for the Activation of Akt and p70S6k. Journal of Biological Chemistry, 1998, 273, 4776-4782.	3.4	110
39	Phosphorylation of Nuclear Phospholipase C Î²1 by Extracellular Signal-Regulated Kinase Mediates the Mitogenic Action of Insulin-Like Growth Factor I. Molecular and Cellular Biology, 2001, 21, 2981-2990.	2.3	107
40	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research, 2017, 23, 1862-1874.	7.0	107
41	The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 821-829.	1.9	105
42	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discovery, 2016, 6, 59-70.	9.4	105
43	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.9	100
44	The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. Journal of Biological Chemistry, 1993, 268, 16091-4.	3.4	100
45	Phosphorylation site sequence of smooth muscle myosin light chain (M r = 20 000). FEBS Letters, 1984, 168, 108-112.	2.8	99
46	Dual Requirement for a Newly Identified Phosphorylation Site in p70^{s6k}. Molecular and Cellular Biology, 1997, 17, 5648-5655.	2.3	99
47	[24] Pseudosubstrate-based peptide inhibitors. Methods in Enzymology, 1991, 201, 287-304.	1.0	94
48	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget, 2016, 7, 49800-49818.	1.8	93
49	Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood, 2008, 112, 2305-2317.	1.4	92
50	Role of basic residues in the phosphorylation of synthetic peptides by myosin light chain kinase.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 7471-7475.	7.1	90
51	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature Communications, 2020, 11, 2641.	12.8	90
52	How the evolution of multicellularity set the stage for cancer. British Journal of Cancer, 2018, 118, 145-152.	6.4	89
53	Direct Identification of Tyrosine 474 as a Regulatory Phosphorylation Site for the Akt Protein Kinase. Journal of Biological Chemistry, 2002, 277, 38021-38028.	3.4	88
54	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. Cancer Research, 2006, 66, 11718-11725.	0.9	85

#	Article	IF	Citations
55	Mutation analysis ofPIK3CA andPIK3CB in esophageal cancer and Barrett's esophagus. International Journal of Cancer, 2006, 118, 2644-2646.	5.1	83
56	Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17990-18000.	7.1	81
57	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	1.9	80
58	Regulation of rDNA transcription in response to growth factors, nutrients and energy. Gene, 2015, 556, 27-34.	2.2	79
59	Spatial requirements for location of basic residues in peptide substrates for smooth muscle myosin light chain kinase. Journal of Biological Chemistry, 1985, 260, 3355-9.	3.4	79
60	Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes, 2017, 8, 71.	2.4	78
61	The Inositol Polyphosphate 5-Phosphatase, PIPP, Is a Novel Regulator of Phosphoinositide 3-Kinase-dependent Neurite Elongation. Molecular Biology of the Cell, 2006, 17, 607-622.	2.1	77
62	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	1.4	74
63	CystathionineÎ²-Synthase in Physiology and Cancer. BioMed Research International, 2018, 2018, 1-11.	1.9	74
64	Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis. PLoS Genetics, 2013, 9, e1003279.	3.5	73
65	AKT-independent PI3-K signaling in cancer – emerging role for SGK3. Cancer Management and Research, 2013, 5, 281.	1.9	73
66	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. European Journal of Cancer, 2013, 49, 3936-3944.	2.8	72
67	Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4737-4742.	7.1	72
68	Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells. PLoS ONE, 2014, 9, e88950.	2.5	69
69	The multi-layered regulation of copper translocating P-type ATPases. BioMetals, 2009, 22, 177-190.	4.1	64
70	Smooth muscle myosin kinase requires residues on the COOH-terminal side of the phosphorylation site. Peptide inhibitors. Journal of Biological Chemistry, 1986, 261, 25-7.	3.4	62
71	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood, 2013, 121, 2964-2974.	1.4	59
72	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 5539-5552.	7.0	59

#	Article	IF	Citations
73	The mTORC1 Inhibitor Everolimus Prevents and Treats EÎ¼-Myc Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery, 2013, 3, 82-95.	9.4	58
74	Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19635-19645.	7.1	58
75	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naÃ¯ve melanoma but not after the development of BRAF inhibitor resistance. International Journal of Cancer, 2018, 142, 2139-2152.	5.1	56
76	Targeting RNA polymerase I transcription and the nucleolus for cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 873-878.	3.4	55
77	Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex. Biochemical Journal, 2003, 370, 469-477.	3.7	52
78	Phosphorylation regulates copper-responsive trafficking of the Menkes copper transporting P-type ATPase. International Journal of Biochemistry and Cell Biology, 2009, 41, 2403-2412.	2.8	52
79	Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer. Clinical Cancer Research, 2013, 19, 1411-1421.	7.0	52
80	A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes. Genome Research, 2015, 25, 201-212.	5.5	52
81	Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer. ELife, 2019, 8, .	6.0	50
82	Oncogene-induced senescence: From biology to therapy. Mechanisms of Ageing and Development, 2020, 187, 111229.	4.6	48
83	Regulation of p70s6k/p85s6k and its role in the cell cycle. , 1995, 1, 21-32.		41
84	A functional genetic screen defines the AKT-induced senescence signaling network. Cell Death and Differentiation, 2020, 27, 725-741.	11.2	40
85	Akt1 is the principal Akt isoform regulating apoptosis in limiting cytokine concentrations. Cell Death and Differentiation, 2013, 20, 1341-1349.	11.2	37
86	Expression of stress response protein glucose regulated protein-78 mediated by c-Myb. International Journal of Biochemistry and Cell Biology, 2005, 37, 1254-1268.	2.8	36
87	Signaling to the ribosome in cancerâ€"It is more than just mTORC1. IUBMB Life, 2011, 63, 79-85.	3.4	35
88	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. Communications Biology, 2019, 2, 39.	4.4	33
89	Drosophila Ribosomal Protein Mutants Control Tissue Growth Non-Autonomously via Effects on the Prothoracic Gland and Ecdysone. PLoS Genetics, 2011, 7, e1002408.	3.5	31
90	Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin. Cell Death and Differentiation, 2018, 25, 1146-1159.	11.2	31

#	Article	IF	Citations
91	Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 787-791.	1.1	30
92	Regulation of protein kinases by pseudosubstrate prototopes. Cellular Signalling, 1989, 1, 303-311.	3.6	29
93	Protein kinase-dependent phosphorylation of the Menkes copper P-type ATPase. Biochemical and Biophysical Research Communications, 2003, 303, 337-342.	2.1	29
94	Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation. Blood, 2010, 115, 344-352.	1.4	29
95	Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy. Hypertension, 2011, 57, 973-980.	2.7	27
96	Proteolytic cleavage sites in smooth muscle myosin-light-chain kinase and their relation to structural and regulatory domains. FEBS Journal, 1991, 200, 723-730.	0.2	26
97	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	4.1	26
98	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. British Journal of Cancer, 2021, 124, 616-627.	6.4	26
99	Insulin and insulin antagonists evoke phosphorylation of P20 at serine 157 and serine 16 respectively in rat skeletal muscle. FEBS Letters, 1999, 462, 25-30.	2.8	25
100	PR55Î±-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene, 2015, 34, 1333-1339.	5.9	21
101	Phosphorylation of a synthetic heptadecapeptide by smooth muscle myosin light chain kinase. Journal of Biological Chemistry, 1982, 257, 13349-53.	3.4	21
102	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2017, 18, 210.	4.1	20
103	<scp>AKT</scp> signalling is required for ribosomal <scp>RNA</scp> synthesis and progression of <scp>E</scp>Î¼â€Myc <scp>B</scp>â€cell lymphoma inÂvivo. FEBS Journal, 2013, 280, 5307-5316.	4.7	19
104	Myosin light chain kinase binding to plastic. FEBS Letters, 1982, 145, 327-331.	2.8	17
105	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene, 2019, 38, 3824-3842.	5.9	17
106	Reprogrammed <scp>mRNA</scp> translation drives resistance to therapeutic targeting of ribosome biogenesis. EMBO Journal, 2020, 39, e105111.	7.8	17
107	The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function. Nature Cell Biology, 2021, 23, 1136-1147.	10.3	17
108	The Synthetic Peptide RPRAATF Allows Specific Assay of Akt Activity in Cell Lysates. Analytical Biochemistry, 2002, 305, 32-39.	2.4	16

#	Article	IF	Citations
109	A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. Cellular Signalling, 2011, 23, 1338-1347.	3.6	16
110	Relative Expression Levels Rather Than Specific Activity Plays the Major Role in DeterminingIn VivoAKT Isoform Substrate Specificity. Enzyme Research, 2011, 2011, 1-18.	1.8	16
111	Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70s6k/p85s6k: implications for the analysis of S6K signalling. FEBS Letters, 2002, 519, 135-140.	2.8	15
112	S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila. Cellular Signalling, 2015, 27, 2045-2053.	3.6	15
113	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461. Frontiers in Cell and Developmental Biology, 2020, 8, 568.	3.7	15
114	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYCâ€“Driven Cancer Progression. Cancer Research, 2020, 80, 3706-3718.	0.9	15
115	Effects of wortmannin and rapamycin on CSF-1-mediated responses in macrophages. International Journal of Biochemistry and Cell Biology, 1998, 30, 271-283.	2.8	14
116	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription. Gene, 2017, 612, 36-48.	2.2	14
117	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood, 2021, 137, 3351-3364.	1.4	13
118	Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity. BMC Biochemistry, 2012, 13, 30.	4.4	9
119	CX-5461 Sensitizes DNA Damage Repairâ€“proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	4.1	9
120	Cystathionine-Î²-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation. ELife, 0, 11, .	6.0	9
121	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. Oncotarget, 2016, 7, 48887-48904.	1.8	8
122	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. Assay and Drug Development Technologies, 2016, 14, 416-428.	1.2	8
123	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma. Nature Communications, 2022, 13, 1100.	12.8	8
124	In silico modeling of the Menkes copper-translocating P-type ATPase 3rd metal binding domain predicts that phosphorylation regulates copper-binding. BioMetals, 2011, 24, 477-487.	4.1	6
125	Hydroxyamino acid specificity of smooth muscle myosin light chain kinase. Archives of Biochemistry and Biophysics, 1988, 260, 37-44.	3.0	5
126	Unexpected role of CDK4 in a G2/M checkpoint. Cell Cycle, 2015, 14, 1351-1352.	2.6	5

#	Article	IF	Citations
127	Role of the pseudosubstrate sequence in smooth muscle myosin light chain kinase thermal stability. Journal of Biological Chemistry, 1993, 268, 12484-91.	3.4	5
128	Too much or too little. Cell Cycle, 2012, 11, 3147-3148.	2.6	4
129	Chemical modification of lysine and arginine residues in the myosin regulatory light chain inhibits phosphorylation. BBA - Proteins and Proteomics, 1986, 870, 312-319.	2.1	3
130	Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias. Blood, 2011, 118, 1548-1548.	1.4	2
131	CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer. Molecular and Cellular Oncology, 2020, 7, 1805256.	0.7	1
132	Dual posttranscriptional targets of retinoic acid-induced gene expression. Journal of Cellular Biochemistry, 1999, 72, 411-422.	2.6	0
133	Signaling to the ribosome in cancer-It is more than just mTORC1. IUBMB Life, 2011, 63, spcone-spcone.	3.4	0
134	A High-Throughput Screening Approach to Identify Therapeutics for the Treatment of Diamond-Blackfan Anaemia. Blood, 2018, 132, 3859-3859.	1.4	0